Equities research analysts at StockNews.com assumed coverage on shares of Bio-Path (NASDAQ:BPTH – Get Free Report) in a research report issued to clients and investors on Wednesday. The brokerage set a “sell” rating on the stock.
Separately, Roth Mkm restated a “buy” rating and set a $40.00 price target on shares of Bio-Path in a report on Thursday, April 18th.
Read Our Latest Stock Report on BPTH
Bio-Path Stock Performance
Bio-Path (NASDAQ:BPTH – Get Free Report) last issued its earnings results on Friday, March 8th. The company reported ($5.40) earnings per share for the quarter, meeting analysts’ consensus estimates of ($5.40). During the same quarter last year, the business posted ($10.60) earnings per share. As a group, research analysts forecast that Bio-Path will post -18.71 EPS for the current fiscal year.
About Bio-Path
Bio-Path Holdings, Inc operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction.
Recommended Stories
- Five stocks we like better than Bio-Path
- How to Read Stock Charts for Beginners
- Hasbro’s Management Made All the Right Calls This Quarter
- Stock Dividend Cuts Happen Are You Ready?
- Caterpillar’s Market Reset Isn’t Over: Get Ready for Lower Prices
- What is the FTSE 100 index?
- Power Surge: Utilities Sector’s Resilience Shines
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.